A disease caused by hyperplastic process of non-transformed prostatic cells.
| Excerpt | Reference |
|---|
| "This suggests that medical treatment of prostatic adenoma might be feasible using substances inhibiting the 5alpha-reduction of testosterone." | ( Bercovici, JP; Charles, JF; Morfin, R, 1975) |
| "In 30-40% of the men the prostatic adenoma causes obstruction which requires operative treatment." | ( Bonvin, B; Hauri, D; Schmucki, O, 1976) |
| "Conservative therapy of benign prostatic hypertrophy comprises the administration of oestrogens, gestagens, androgens and anti-androgens." | ( Englisch, M; Flamm, J; Kiesswetter, H, 1979) |
| "The authors treated 23 benign prostatic hyperplasia (BPH) patients with antiandrogen flutamide." | ( Bach, D; Romics, I, 1992) |
| "Twenty-three men with benign prostatic hyperplasia (BPH) were included in this study; eight received placebo, seven were allocated to treatment with 1 mg/day, and eight to 5 mg/day finasteride for 12 months." | ( Braf, Z; Chen, J; Goldray, D; Jaccard, N; Matzkin, H; Pappas, F; Weisman, Y, 1992) |
| "The treatment of benign prostatic hyperplasia with 5 mg of finasteride per day results in a significant decrease in symptoms of obstruction, an increase in urinary flow, and a decrease in prostatic volume, but at a slightly increased risk of sexual dysfunction." | ( Andriole, GL; Bracken, BR; Bruskewitz, RC; Geller, J; Gormley, GJ; Imperato-McGinley, J; McConnell, JD; Stoner, E; Tenover, JS; Walsh, PC, 1992) |
| "Fifty-eight normotensive patients with benign prostatic hyperplasia and maximum urinary flow rates of less than 15 ml/s were randomly assigned to receive a 12-week course of treatment with prazosin or placebo in a double-blind parallel group trial." | ( Chapple, CR; Christmas, TJ; Milroy, EJ, 1990) |
| "Benign prostatic hypertrophy, a common ailment among elderly men, usually is treated by surgery." | ( Braf, Z; Chen, J; Lewysohn, O; Matzkin, H, 1991) |
| "Forty-four patients with benign prostatic hypertrophy treated with transurethral resection of the prostate were entered in this study." | ( Morita, M; Nakagawa, H; Suzuki, K, 1991) |
| "A total of 4 men with benign prostatic hypertrophy who underwent medical castration therapy with a long-acting gonadotropin-releasing hormone agonist (leuprolide) for more than 6 months elected to add an estrogen transdermal patch (0." | ( Droller, M; Gabrilove, JL; Kirschenbaum, A; Levine, AC, 1991) |
| "Our trial suggests that the treatment of benign prostatic hypertrophy with allylestrenol can be useful in urological clinics." | ( Aso, Y; Hata, M; Kambayashi, T; Kitagawa, M; Masuda, H; Nakahara, M; Ohmi, Y; Suzuki, A; Tajima, A; Ushiyama, T, 1986) |
| "Seventeen patients with benign prostatic hypertrophy were treated with 50 mg allylestrenol per day for a long period of time (mean: 37." | ( Fujii, N; Haraguchi, C; Higaki, Y; Imamura, K; Ohyama, M; Tanifuji, T; Yoshida, H, 1986) |
| "Patients with benign prostatic hypertrophy (BPH) were treated with MA (160 mg/day) plus KC (1,200 mg/day) for 7 days." | ( Albert, J; Geller, J; Liu, J, 1986) |
| "Ten males had a history of prostatic hypertrophy and in these patients treatment with bumetanide was not beneficial." | ( Johansen, PB; Pedersen, PA, 1988) |
| "Conservative treatment of benign prostatic hyperplasia with the antiandrogen oxendolone in a dose of 200 mg a week cannot be recommended for clinical use." | ( Andersson, T; Frimodt-Møller, C; Lindgård, G; Meyhoff, HH; Nielsen, MS; Ostri, P; Petersen, JH; Swartz, R, 1989) |
| "Seven patients with benign prostatic hyperplasia were treated for six months with nafarelin acetate and then followed for an additional six months." | ( Chan, DW; Oesterling, JE; Partin, AW; Peters, CA; Walsh, PC; Weber, JP, 1989) |
| "For patients with symptomatic benign prostatic hyperplasia who are not candidates for surgery, treatment with an LH-RH agonist, such as leuprolide acetate, should be considered as a possible alternative." | ( Brendler, CB; Schlegel, PN, 1989) |
| "Pathogenesis and therapy of benign prostatic hypertrophy (BPH) are reviewed." | ( Geller, J, 1989) |
| "Thus, the false positive rate of benign prostatic hyperplasia was estimated at 9% and false negative rate of untreated prostatic carcinoma at 27%." | ( Ikemoto, I; Imanaka, K; Machida, T; Oishi, Y; Onishi, T; Shirai, T, 1989) |
| "It is concluded that non-treated benign prostatic hyperplasia lacks L-histidine ammonia lyase activity and subsequently the metabolic pathway of histidine." | ( Van Camp, K; van Sande, M, 1980) |
| "Results show that in untreated benign prostatic hyperplasia there is a statistically lower lactoferrin level in the median compared with the lateral lobes." | ( Van Camp, K; van Sande, M, 1981) |
| "We studied 20 patients with benign prostatic hyperplasia, 27 with untreated prostatic cancer without bone metastases and 11 with metastases, in addition to 7 with cancer treated by hormonal therapy." | ( Kontturi, M; Lukkarinen, O; Vihko, P; Vihko, R, 1982) |
| "Treatment of 9 patients with benign prostatic hyperplasia with 20 mg tamoxifen daily for 6 weeks resulted in a significant increase of LH (211%), FSH (215%), E2 (231%), total T (157%), free T (148%) and total DHT (148%) levels in blood." | ( Dörner, G; Geier, T; Poppe, I; Rohde, W; Schnorr, D; Stahl, F, 1983) |
| "The results show that in treated benign prostatic hyperplasia there is a lower polyamine concentration." | ( Van Berendonckx, J; Van Camp, K; van Sande, M, 1983) |
| "Twenty patients with benign prostatic hypertrophy were treated with an anti-androgenic agent, chlormadinone acetate ( Prostal ), 50 mg daily for 3 months." | ( Haraguchi, C; Higaki, Y; Imamura, K; Kawai, N; Ogawa, Y; Ohyama, M; Saitoh, T; Yoshida, H, 1983) |
| "Eight dogs with spontaneous benign prostatic hyperplasia were treated with daily subcutaneous injections of 25 micrograms of Buserelin, (D-Ser(TBU)6,des-Gly-NH2(10))ethylamide during 3 months." | ( Bélanger, A; Dubé, JY; Frenette, G; Tremblay, RR; Tremblay, Y, 1984) |
| "Forty-three patients with benign prostatic hyperplasia were treated with weekly i." | ( Fujii, M; Fujiwara, H; Kitano, T; Kodama, M; Matsuki, S; Nihira, H; Sagami, K; Tado, O; Ukai, R; Yasukawa, A, 1984) |
| "Bladder outlet obstruction in men with benign prostatic hyperplasia is decreased following administration of prazosin, a selective alpha1 adrenergic antagonist." | ( Lepor, H; Shapiro, E, 1984) |
| "Alternative treatments for benign prostatic hyperplasia (BPH) are the source of much discussion at present." | ( Chapple, CR; Milroy, EJ; Noble, JG, 1993) |
| "Antiandrogen therapy for benign prostatic hyperplasia (BPH) and prostatic carcinoma has been introduced in clinical practice." | ( Hasegawa, F; Isurugi, K; Takahashi, S, 1994) |
| "Eighty patients with benign prostatic hypertrophy were each treated with the antiandrogen agents, chlormadinone acetate, allylestrenol, gestonolone caproate and oxendolone for 12 months." | ( Iguchi, H; Ikeuchi, T; Kai, Y; Yoshida, H, 1994) |
| "The International Consultation of Benign Prostatic Hyperplasia (Paris, June 1991) concluded that, to date, phytotherapeutic agents must be considered as a symptomatic treatment." | ( Buscarini, M; Caponera, M; D'Eramo, G; Di Silverio, F; Flammia, GP; Mauro, M; Sciarra, A; Tavani, M, 1993) |
| "Twenty-three patients with symptomatic benign prostatic hyperplasia (BPH) were treated with finasteride (5 mg/d) for 12 months and underwent transrectal ultrasound (TRUS) evaluation of total and TZ volume of prostate and measurement of peak flow rate and modified Boyarsky symptom score at baseline and at 12 months." | ( Narayan, P; Shinohara, K; Tewari, A, 1995) |
| "A total of 21 patients with benign prostatic hyperplasia was treated with finasteride to evaluate the variation of prostatic volumes and PSA values." | ( Dell'Orto, P; Trinchieri, A, 1995) |
| "Ten beagle dogs (4-8 years of age) with benign prostatic hypertrophy were treated daily for 7 or 14 days by a daily oral administration of chlormadinone acetate (CMA), an anti-androgenic preparation, at a dose of 0." | ( Kawakami, E; Ogasa, A; Orima, H; Shimizu, M; Tsutsui, T, 1995) |
| "Medical management of benign prostatic hyperplasia (BPH) is an alternative to surgical treatment of this disease." | ( Breslin, D; Chou, TC; Felsen, D; Fields, DW; Kane, M; Marion, DN; Vaughan, ED, 1993) |
| "Forty four patients with benign prostatic hypertrophy treated with transurethral resection of the prostate (TUR-P) were entered in this study." | ( Hatakeyama, T; Morita, M; Suzuki, K, 1993) |
| "Fifty patients with benign prostatic hypertrophy were treated with chlormadinone acetate (CMA) at the dose of 50 mg/day for 12 months." | ( Higashino, I; Kido, K; Kogawa, T; Kudo, T; Mikuni, T; Suzuki, T; Takashima, T; Tsukui, A; Yagihashi, Y; Yanagiya, H, 1993) |
| "In men with symptomatic benign prostatic hyperplasia (BPH), these effects have been associated with improvements in peak urinary flow rate and urological symptoms; withdrawal from therapy, however, results in regrowth of the adenoma and long term therapy is therefore necessary." | ( Peters, DH; Sorkin, EM, 1993) |
| "Twelve patients with benign prostatic hyperplasia received a total of four single oral doses of 18 mg/kg antipyrine before, during, and after treatment with 10 mg/day of finasteride for 28 days." | ( Gregoire, S; Hegland, J; Hunninghake, DB; Taylor, AM; Winchell, GA, 1993) |
| "Men with benign prostatic hyperplasia can be treated with alpha 1-adrenergic-antagonist drugs that relax prostatic smooth muscle or with drugs that inhibit 5 alpha-reductase and therefore reduce tissue androgen concentrations." | ( Barry, MJ; Brawer, MK; Dixon, CM; Gormley, G; Haakenson, C; Lepor, H; Machi, M; Narayan, P; Padley, RJ; Williford, WO, 1996) |
| "In men with benign prostatic hyperplasia, terazosin was effective therapy, whereas finasteride was not, and the combination of terazosin and finasteride was no more effective than terazosin alone." | ( Barry, MJ; Brawer, MK; Dixon, CM; Gormley, G; Haakenson, C; Lepor, H; Machi, M; Narayan, P; Padley, RJ; Williford, WO, 1996) |
| "40 patients with symptomatic benign prostatic hyperplasia were treated with 0." | ( Sakai, S; Shimazaki, J, 1996) |
| "A total of 89 patients with benign prostatic hyperplasia (BPH) were treated pharmacologically for 4 months: 51 received Cernilton and 38 Tadenan (controls)." | ( Dutkiewicz, S, 1996) |
| "A subset of patients with benign prostatic hyperplasia may benefit from treatment with finasteride." | ( Huang, JK; Jiaan, BP; Lee, YH; Wu, TT, 1995) |
| "Sixty patients with symptomatic benign prostatic hypertrophy (BPH) were treated with tamsulosin hydrochloride (0." | ( Fujita, K; Kawabe, K; Kurita, Y; Suzuki, K; Ushiyama, T, 1996) |
| "To investigate in men with benign prostatic hyperplasia (BPH) treated in the general practitioner setting (1) the magnitude and durability of symptom score improvement with alfuzosin; (2) the effect on patients perceived health-related quality of life (HRQL) and sexuality, (3) adverse outcomes and treatment failure; and (4) progression to acute urinary retention and prostate surgery." | ( Jardin, A; Leplège, A; Lukacs, B; Thibault, P, 1996) |
| "Men with moderate symptoms of benign prostatic hyperplasia (BPH) are the best candidates for medical treatment, while surgery is usually indicated for patients with severe symptoms." | ( Eri, LM; Tveter, KJ, 1997) |
| "Thirty-four patients with symptomatic benign prostatic hypertrophy who were candidates for traditional TURP were treated with contact laser ablation of the prostate (CLAP)." | ( Gomella, LG; Lotfi, MA; Reagan, GN, 1995) |
| "Minimally invasive treatments for benign prostatic hyperplasia (BPH) are currently very controversial." | ( Briner, J; Hauri, D; Huch Böni, RA; Jochum, W; Krestin, GP; Sulser, T, 1997) |
| "Fifty-two patients with benign prostatic hyperplasia treated with transurethral resection of the prostate were entered in this study." | ( Morita, M; Numahata, K; Ogata, Y; Suzuki, K, 1997) |
| "We identified 69 men with symptomatic benign prostatic hyperplasia (BPH) who had been receiving 5 mg/day (n = 33) of finasteride or 2 to 5 mg/day (n = 14) of terazosin or no therapy ("watchful waiting") (n = 22)." | ( Andriole, GL; Catalona, WJ; Keetch, DW; Ratliff, TL, 1997) |
| "40 patients with benign prostatic hyperplasia (BPH) were treated with the alpha-blocker alfuzosin which was administered per os twice a day in a dose 5 mg." | ( Matushevskiĭ, IA; Mazo, EB; Nikitin, IuIu, 1997) |
| "A total of 3,228 patients with clinical benign prostatic hyperplasia (BPH) from 812 centers were included in a prospective 3-year open-labeled study and treated with alfuzosin (immediate-release formulation) at the recommended dosage." | ( Comet, D; Grange, JC; Lukacs, B; McCarthy, C, 1998) |
| "Whether incontinence after surgery for benign prostatic hypertrophy (BPH) requires simple workup and treatment or being a more complex condition and multifactorial in etiology requiring combined surgical techniques should be investigated in more detail." | ( Floratos, D; Katsifotis, C; Mertziotis, N; Moutzouris, G; Plastiras, D; Theodorou, C, 1998) |
| "Finasteride therapy for benign prostatic hyperplasia (BPH) results in a marked lowering of serum prostate specific antigen (PSA) levels." | ( Chan, DW; Gormley, GJ; Kelley, CA; Marks, LS; Pannek, J; Partin, AW; Pearson, JD; Rittenhouse, HG; Shery, ED; Stoner, E; Subong, EN, 1998) |
| "A total of 35 patients with benign prostatic hyperplasia (BPH) were treated with the Ho: YAG laser using a new technique termed holmium laser resection of the prostate or HoLRP." | ( Iida, S; Matsuoka, K; Noda, S; Shimada, A; Suekane, S; Tomiyasu, K, 1998) |
| "Eight beagles with benign prostatic hypertrophy (BPH) were treated by subcutaneous implantation of pellets containing 10 mg/kg chlormadinone acetate (CMA), a synthetic anti-androgen, plus daily oral administration of CMA at 2 mg/kg per day for 7 days as a therapy for BPH." | ( Fujita, M; Hori, T; Kawakami, E; Orima, H; Shimizu, M; Tsutsui, T, 1998) |
| "Since 1986, benign prostatic hyperplasia has been treated with lasers, but clinical use was not practical until the right-angled fiber was developed in the early 1990s." | ( Stein, BS, 1998) |
| "Although benign prostatic hyperplasia, a common condition among elderly men, has been effectively treated with transurethral resection of the prostate, this surgical procedure is associated with many well-recognized risks and complications." | ( Barrett, DM; Darson, MF, 1998) |
| "Not until 1991 did laser therapy for benign prostatic hyperplasia become a feasible option for the practicing urologist." | ( Costello, AJ; Kabalin, JN, 1999) |
| "Medical management of benign prostatic hyperplasia (BPH) giving rise to lower urinary tract symptomatology (LUTS) has emerged as the mainstay for first-line therapy." | ( Brawer, MK; Jones, K; Lepor, H; Lin, DW; Williford, WO, 1999) |
| "A total of 82 patients with benign prostatic hyperplasia successfully treated with 4 mg." | ( Emery, RT; Ferguson, SF; Johnson, DE; MacDiarmid, SA; McGuirt-Franklin, R; McIntyre, WJ, 1999) |
| "The other cases were from patients with benign prostatic hyperplasia and chronically treated with finasteride." | ( Bartels, PH; Duval da Silva, V; Mazzucchelli, R; Montironi, R; Pomante, R; Thompson, D; Vaught, L, 1999) |
| "Treatment of patients with obstructive benign prostatic hypertrophy (BPH) with the drug Finasteride leads to a moderately improved urinary flow, symptomatic improvement and halts the natural progress of the disease." | ( Ekman, P, 1999) |
| "Nine clinical benign prostatic hyperplasia (BPH) patients were treated with oral terazoin monotherapy (2 mg daily) for 12 weeks." | ( Kageyama, S; Tamaki, M; Ueda, T, 1999) |
| "africanum for the treatment of benign prostatic hyperplasia is limited by the short duration of studies and the variability in study design, the use of phytotherapeutic preparations, and the types of reported outcomes." | ( Ishani, A; MacDonald, R; Nelson, D; Rutks, I; Wilt, TJ, 2000) |
| "Medical treatment of benign prostatic hyperplasia (BPH) targets relief of symptoms by causing either relaxation of the prostatic smooth muscle with alpha1 adrenergic blockade, or shrinkage of the gland with 5alpha-reductase inhibitors." | ( Borkowski, A; Chon, JK; Glassman, DT; Jacobs, SC; Kyprianou, N, 2001) |
| "Treatment of benign prostatic hyperplasia (BPH) with nonselective alpha1 antagonists such as terazosin, doxazosin, and prazosin results in blood pressure reduction due to vasodilation." | ( Chao, J; Chrischilles, E; Gilden, D; Kreder, KJ; Rubenstein, L; Shah, H, 2001) |
| "A total of 34 men with benign prostatic hyperplasia (BPH) who have been on terazosin treatment (for the obstructive symptoms) were pathologically diagnosed with prostate cancer following surgery." | ( Borkowski, A; Isaacs, JT; Jacobs, SC; Keledjian, K; Kim, G; Kyprianou, N, 2001) |
| "For treating benign prostatic hyperplasia (BPH) 5 or 10 mg." | ( Furuya, S; Itoh, N; Masumori, N; Ogura, H; Sato, Y; Takahashi, A; Tanaka, Y; Tsukamoto, T, 2002) |
| "Symptomatic benign prostatic hyperplasia (BPH), which a man has a 50% chance of developing during the course of his lifetime, should receive stage-related treatment." | ( Vahlensieck, W, 2002) |
| "Because benign prostatic hyperplasia (BPH) is relatively common, it is important to discover safe and effective means to treat this often debilitating perturbation." | ( Jones, WA; Klimberg, IW; Marcusen, C; Preuss, HG; Regan, J; Welebir, TA, 2001) |
| "In the treatment of the symptoms of benign prostatic hyperplasia (BPH), a French guideline opposes the use of drugs in conjunction, in the absence of proven utility." | ( Billebaud, T; Coulange, C; Gattegno, B; Glemain, P; Loeb, G; Muszynski, R, 2002) |
| "Prostate cancer cell lines and benign prostatic hyperplasia derived epithelial cells were cultured and treated with P." | ( Morote Robles, J; Paciucci Barzanti, R; Reventós Puigjaner, J; Santa María Margalef, A; Thomson Okatsu, TM, 2003) |
| "Medical treatment for benign prostatic hyperplasia is reviewed by the author." | ( Romics, I, 2003) |
| "Medical treatment for the symptoms of benign prostatic hyperplasia (BPH) consists of a blockers and 5-alpha-reductase inhibitors." | ( Sandhu, JS; Te, AE, 2004) |
| "Doxazosin is now being used to treat benign prostatic hyperplasia (BPH)." | ( Doggrell, SA, 2004) |
| "Twenty-two men with benign prostatic hyperplasia who were treated with a nonselective alpha 1-blocker (urapidil) were included." | ( Kumon, H; Nishiguchi, J; Nose, H; Ozawa, H; Watanabe, Y; Yokoyama, T, 2004) |
| "The search terms were benign prostatic hyperplasia treatment, alpha(1)-adrenergic-receptor blocker, uroselectivity, lower urinary tract symptoms, complications, and cardiovascular." | ( Lowe, FC, 2004) |
| "The therapeutic goal of treating benign prostatic hyperplasia (BPH) through early detection and effective therapy is to relieve the symptoms, improve patients' quality of life, decrease postvoid residual urine volume, and prevent the associated morbidity when the condition remains untreated." | ( Desgrandchamps, F; Fitzpatrick, JM, 2005) |
| "The treatment of benign prostatic hyperplasia (BPH), a common problem faced by aging men, has changed dramatically during the last decade." | ( Jacobsen, SJ; Jacobson, DJ; Lieber, MM; McGree, ME; Roberts, RO; Sarma, AV, 2005) |
| "Candidates for TURP among patients with benign prostatic hyperplasia were randomized to either treatment with CMA (CMA+) or not (CMA-)." | ( Kanazawa, M; Kawauchi, A; Kojima, M; Miki, T; Miyashita, H; Nakanouchi, T; Ukimura, O; Yoneda, K, 2005) |
| "To determine the onset of improvement in benign prostatic hyperplasia symptoms in patients after treatment with doxazosin gastrointestinal therapeutic system (DOX GITS) versus placebo." | ( Andersen, M; Kirby, R; Mallen, S; Prajsner, A; Quinn, S; Roehrborn, CG, 2005) |
| "In men with symptomatic benign prostatic hyperplasia, long-term (4-year) treatment with the dual isozyme 5alpha-reductase inhibitor dutasteride resulted in sustained and continued improvements in symptoms and flow rate." | ( Lukkarinen, O; Mark, S; Ramsdell, J; Roehrborn, CG; Siami, P; Zinner, N, 2005) |
| "Obstructive benign prostatic hyperplasia in 94 men was treated with transurethral near contact vaporization with potassium-titanyl-phosphate laser with the patient under general or spinal anesthesia." | ( Barrett, DM; Kuntzman, RS; Malek, RS, 2005) |
| "Early treatment of benign prostatic hyperplasia (BPH) helps to decrease the need for surgery and thus places the medical treatment at the forefront which implies, optimising its efficacy and tolerance." | ( Comaru-Schally, dM, 2005) |
| "Search terms included benign prostatic hyperplasia, alfuzosin, treatment, alpha(1)-adrenergic receptor blocker, long-term, followup, lower urinary tract symptoms, complications or adverse events, sexual, retention and cardiovascular." | ( McVary, KT, 2006) |
| "We have treated both bladder tumor and benign prostatic hyperplasia cases with this new system." | ( Adachi, T; Funao, K; Kobayakawa, H; Matsuyama, M; Nakatani, T; Takemoto, Y; Tsuchida, K; Yoshimura, R, 2006) |
| "Various treatment strategies for benign prostatic hyperplasia (BPH)/LUTS may affect sexuality, with differences between drug classes and between drugs within a same class." | ( Giuliano, F, 2006) |
| "Antiandrogens used to treat benign prostatic hyperplasia (BPH) may affect the diagnosis of prostate cancer by decreasing serum prostate-specific antigen (PSA) values." | ( Arai, Y; Fujimoto, K; Hirao, Y; Kato, T; Masumori, N; Miyazawa, K; Yamanaka, H, 2006) |
| "Hormone treatment induced benign prostatic hyperplasia and resulted in detrusor overactivity, as determined by cystometry." | ( Akiyama, K; Kobayashi, M; Tatemichi, S; Uruno, T; Yamazaki, Y; Yokoyama, O, 2006) |
| "Finasteride administration in benign prostatic hyperplasia results in statistically significant suppression of MVD, VEGF, and HIF-1alpha in a time-dependent manner." | ( Chrisofos, M; Deliveliotis, C; Lappas, D; Lazaris, AC; Lekas, AG; Papatsoris, AG; Patsouris, E, 2006) |
| "Medical treatment for symptomatic Benign Prostatic Hyperplasia (BPH) has become popular for the last few years." | ( Anwarul Islam, AK; Kashem, MA; Kibria, SA; Shameem, IA, 2005) |
| "The surgical treatment of benign prostatic hyperplasia is a dynamic, evolving field." | ( Lingeman, JE; Matlaga, BR; Miller, NL, 2007) |
| "The management of benign prostatic hyperplasia was transurethral resection of prostate until simpler and alternative treatments were tried in the last two decades, particularly alpha(1) adrenoceptor-blocking agents." | ( Grey, AD; Nargund, VH, 2008) |
| "Patients with benign prostatic hyperplasia and erectile dysfunction treated with the doxazosin gastrointestinal therapeutic system on a regular basis, with no other antihypertensive events, were recruited." | ( Chan, ES; Cheng, CW; Hou, SM; Ng, CF; Wong, A; Wong, HM, 2008) |
| "Nocturia is a well-recognized symptom of benign prostatic hyperplasia (BPH), which is commonly treated by alpha(1)-blockers and/or 5alpha-reductase inhibitors." | ( Asgari, SA; Falahatkar, S; Kamran, AN; Mokhtari, G; Pourreza, F, 2008) |
| "Medical treatment of benign prostatic hyperplasia is reviewed by the author." | ( Romics, I, 2008) |
| "Because aging men are at risk for benign prostatic hyperplasia (BPH) and prostate cancer, elucidating the relationship between testosterone and these diseases is crucial to ensure its safe administration." | ( Crawford, ED; Holyoak, JD; Meacham, RB, 2008) |
| "Laser treatment of benign prostatic hyperplasia has been introduced." | ( Bach, T; Blana, A; Burchardt, M; Ganzer, R; Gross, AJ; Herrmann, TR, 2009) |
| "Among patients with benign prostatic hyperplasia who were treated with a alpha1-adrenoceptor blocker, we administered naftopidil (75 mg/day) for 12 weeks to 85 patients in whom the global severity was evaluated as moderate or severe." | ( Kojima, Y; Miyake, O; Oda, M; Okuyama, A; Tsujihata, M; Uchida, K; Yoshimura, K, 2009) |
| "After his condition was diagnosed as benign prostatic hypertrophy, he started finasteride (FIN, 5 mg/d) treatment." | ( Bortolato, M; Cannas, A; Marrosu, F; Muroni, A; Puligheddu, M; Solla, P, 2010) |
| "The molecular mechanisms underlying benign prostatic hyperplasia are obscure and the development of animal models to test novel treatment strategies is challenging." | ( Di Vizio, D; Freeman, MR; Insabato, L; Pelton, K; Schaffner, CP; Solomon, KR, 2010) |
| "Forty-three patients with benign prostatic hypertrophy with marked urinary distress, which I believed warranted surgical treatment, were selected from private practice." | ( Orkin, LA, 1974) |
| "• Laser treatment of benign prostatic hyperplasia has challenged transurethral resection of the prostate (TURP) due to advances in laser technology, better understanding of tissue-laser interactions and growing clinical experience." | ( Bachmann, A; De La Rosette, J; Gilling, PJ; Gravas, S; Reich, O; Roehrborn, CG, 2011) |
| "Patient preference for benign prostatic hyperplasia (BPH) treatment with the α(1)-blockers, tamsulosin or silodosin, was compared using patient-reported outcomes." | ( Kageyama, S; Ozono, S; Watanabe, T, 2011) |
| "A total of 120 patients with benign prostatic hyperplasia scheduled for high power 980 nm diode laser ablation of the prostate were randomized to receive treatment with the standard side firing fiber or the novel quartz head contact fiber between April 2009 and April 2010." | ( Shaker, HS; Shaker, SH; Shoeb, MS; Yassin, MM, 2012) |
| "Normal and benign prostatic hyperplasia (BPH) model rats were repeatedly treated with S-40542 and flutamide." | ( Furuya, K; Nagata, N; Nejishima, H; Suzuki, M; Yamada, S; Yamamoto, N, 2012) |
| "During a 24-week treatment of benign prostatic hyperplasia with tamsulosin, the same showed clinical efficiency in the sense of improvement of LUTS and a decrease of bladder outlet obstruction (BOO), without the influence on prostate volume or showing statistically significant vasodilatory effect." | ( Milicevic, S, 2012) |
| "Since Benign Prostatic Hyperplasia and Prostate Cancer are two of the most diffuse diseases of aging male and considering that standard medical therapy is accompanied with different side effects, the emerging use of African plants may be justified." | ( Castelli, T; Cimino, S; Favilla, V; Madonia, M; Morgia, G; Russo, GI; Salamone, C, 2013) |
| "The treatment of benign prostatic hyperplasia can be accomplished by the use of different drugs including, doxazosin, an α-1 adrenergic antagonist, and finasteride (FIN), a 5-α reductase inhibitor." | ( Abrahim-Vieira, B; Cabral, LM; De Sousa, VP; Do Carmo, FA; Lopes, M; Padula, C; Pupe, CG; Ribeiro, AJ; Rodrigues, CR; Santi, P; Veiga, F, 2013) |
| "Current treatments for benign prostatic hyperplasia include α1-adrenoceptor antagonists which inhibit smooth muscle contraction." | ( Short, JL; Ventura, S; White, CW, 2013) |
| "In men with symptomatic benign prostatic hyperplasia 5α-reductase inhibitors are a main modality of treatment." | ( Bechis, SK; Ge, R; Olumi, AF; Otsetov, AG; Tabatabaei, S; Vangel, MG; Wang, Z; Wu, CL, 2015) |
| "In patients with benign prostatic hyperplasia, treatment with silodosin significantly increased testosterone secretion, and improvements in objective symptoms such as BOO were found to be the factors that influenced testosterone secretion." | ( Funahashi, Y; Gotoh, M; Hirakawa, A; Kato, M; Matsukawa, Y; Takai, S; Yamamoto, T, 2016) |
| "The standard surgical treatment for benign prostatic hypertrophy (BPH) is transurethral resection of the prostate (TURP)." | ( Ahmed, E; Andersson, E; Fagerström, T; Hahn, RG; Ingvar, J; Norming, U; Nyman, CR, 2017) |
| "We treated 195 patients with benign prostatic hyperplasia (BPH) by HoLEP, using conventional morcellation for 100 cases and modified morcellation for the other 95." | ( Chen, Q; Chen, YB; Gu, M; Wang, Z; Xu, H, 2016) |
| "Treatment of benign prostatic hyperplasia and lower urinary tract symptoms with a continuous low dose of sildenatil seems to be a good treatment choice for the patients with mild to moderate benign prostatic hyperplasia and lower urinary tract symptoms, especially in the patients with concomitant erectile dysfunction." | ( Dozic, S; Grbic, D; Jeremic, D; Levakov, I; Sekulic, V; Vojinov, S, 2016) |
| "Surgical options for benign prostatic hyperplasia (BPH) become limited when treating large prostates due to steep learning curves and less effective treatment." | ( Bhojani, N; Elterman, D; Kaufman, RP; Nguyen, DD; Zorn, KC, 2019) |
| "Correction of benign prostatic hyperplasia (BPH) with lower urinary tract (LUT) symptoms (LUTS) is treated with drugs of different pharmacological classes having side effects including suppression of sexual function." | ( Gainullina, Y; Karashchuk, E; Kosilov, K; Kosilova, L; Kuzina, I; Kuznetsov, V; Loparev, S; Prokofyeva, A, 2018) |
| "Some patients with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms hesitate to undergo surgical treatment until acute urinary retention (AUR) occurs." | ( Chang, YH; Chung, HJ; Huang, WJ; Huang, YH; Kuo, JY; Lin, ATL; Lin, TP; Lu, CH; Lu, SH; Wu, HHH, 2019) |
| "Lasers remain an integral part of benign prostatic hyperplasia surgery and stone treatment and gain popularity in en-bloc resection of bladder cancer." | ( Enikeev, D; Glybochko, P; Shariat, SF; Taratkin, M, 2020) |
| "Pharmacotherapies for the treatment of Benign Prostatic Hyperplasia (BPH) are targeted at reducing cellular proliferation (static component) or reducing smooth muscle tone (dynamic component), but response is unpredictable and many patients fail to respond." | ( Ellem, SJ; Exintaris, B; Frydenberg, M; Hammar, J; Kraska, J; Lawrentschuk, N; Lee, SN; Middendorff, R; Niranjan, B; Papargiris, M; Risbridger, GP; Ryan, A; Teng, L; Whittaker, M, 2021) |
| "Patients with benign prostatic hyperplasia who presented high prostate-specific antigen levels after the first negative prostate biopsy were administered 0." | ( Inoue, T; Kamoto, T; Kinoshita, H; Matsuda, T; Murota, T; Ogawa, O; Terada, N; Tsukino, H; Yoshimura, K, 2021) |
| "Eight intact, 5-11-year-old dogs with benign prostatic hyperplasia were treated orally with OA at a dose of 0." | ( Bedin, S; Contiero, B; Ferré-Dolcet, L; Frigotto, L; Romagnoli, S, 2022) |
| "The AUA guidelines for benign prostatic hyperplasia distinguish treatments based upon prostate volume (PV), particularly for very large prostates (> 150 mL)." | ( Alcantara, KM; Alcantara, M; Elterman, D; Ghiraldi, E; Glaser, AP; Helfand, BT; Higgins, A; Kasraeian, A; Sterious, S; Talaty, P, 2021) |
| "Patients with benign prostatic hyperplasia are usually treated with 5α-reduced inhibitors (5ARIs) such as finasteride and dutasteride." | ( Inoue, T; Kamoto, T; Kawa, G; Kinoshita, H; Matsuda, T; Murota, T; Ogawa, O; Taniguchi, H; Tsukino, H; Yoshimura, K, 2023) |
| "Patients with benign prostatic hyperplasia (BPH) receive α-blockers as first-line therapy to treat lower urinary tract symptoms; however, some individuals still experience residual storage symptoms." | ( Chan, VW; Chen, HL; Lee, HY; Su, YT; Teoh, JY; Wu, WJ, 2023) |